TVARDI THERAPEUTICS, INC.
NASDAQ: TVRD (Tvardi Therapeutics, Inc.)
Kemas kini terakhir: 12 jam lalu22.46
1.01 (4.71%)
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Tvardi Therapeutics, Inc. | - | - |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -4.5 |
Purata Bergerak Teknikal | -3.5 |
Osilator Teknikal | -0.5 |
Purata | -1.38 |
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 27.53% |
% Dimiliki oleh Institusi | 2.76% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Two Sigma Advisers, Lp | 31 Mar 2025 | 16,393 |
Lpl Financial Llc | 31 Mar 2025 | 4,051 |
Arax Advisory Partners | 31 Mar 2025 | 869 |
Lri Investments, Llc | 31 Mar 2025 | 83 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 78.00 (Piper Sandler, 247.28%) | Beli |
Median | 65.00 (189.40%) | |
Rendah | 39.00 (Jones Trading, 73.64%) | Beli |
Purata | 60.67 (170.13%) | |
Jumlah | 3 Beli | |
Harga Purata @ Panggilan | 26.62 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Piper Sandler | 12 Jun 2025 | 78.00 (247.28%) | Beli | 26.11 |
Oppenheimer | 21 May 2025 | 65.00 (189.40%) | Beli | 32.72 |
Jones Trading | 28 Apr 2025 | 39.00 (73.64%) | Beli | 21.02 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
20 May 2025 | Pengumuman | Tvardi Therapeutics to Participate in Upcoming Investor Conferences |
13 May 2025 | Pengumuman | Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update |
06 May 2025 | Pengumuman | Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference |
14 Apr 2025 | Pengumuman | Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |